BRPI0607349A2 - combinação de xolair com agente imunossupressor - Google Patents

combinação de xolair com agente imunossupressor

Info

Publication number
BRPI0607349A2
BRPI0607349A2 BRPI0607349-2A BRPI0607349A BRPI0607349A2 BR PI0607349 A2 BRPI0607349 A2 BR PI0607349A2 BR PI0607349 A BRPI0607349 A BR PI0607349A BR PI0607349 A2 BRPI0607349 A2 BR PI0607349A2
Authority
BR
Brazil
Prior art keywords
xolair
combination
immunosuppressive agent
pharmaceutically acceptable
agent
Prior art date
Application number
BRPI0607349-2A
Other languages
English (en)
Inventor
Charles Edward Owen
Howard George Fox
Christoph Walker
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0607349A2 publication Critical patent/BRPI0607349A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

COMBINAçãO DE XOLAIR COM AGENTE IMUNOSSUPRESSOR. A presente invenção refere-se a uma composição farmacêutica compreendendo um anticorpo anti-IgE e pelo menos um outro agente imunossupressor, na qual os ingredientes ativos estão, em cada caso, na forma livre ou na forma de um sal farmaceuticamente aceitável e opcionalmente pelo menos um carreador farmaceuticamente aceitável; para uso simultâneo, separado ou seqúencial.
BRPI0607349-2A 2005-02-04 2006-02-02 combinação de xolair com agente imunossupressor BRPI0607349A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0502358.5A GB0502358D0 (en) 2005-02-04 2005-02-04 Organic compounds
PCT/EP2006/000911 WO2006082052A1 (en) 2005-02-04 2006-02-02 Synergistic combination of xolair/omalizumab/e25 with immunosuppressive agent

Publications (1)

Publication Number Publication Date
BRPI0607349A2 true BRPI0607349A2 (pt) 2009-09-01

Family

ID=34355808

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0607349-2A BRPI0607349A2 (pt) 2005-02-04 2006-02-02 combinação de xolair com agente imunossupressor

Country Status (20)

Country Link
US (1) US20080206237A1 (pt)
EP (1) EP1846031A1 (pt)
JP (1) JP2008528650A (pt)
KR (1) KR20070100344A (pt)
CN (1) CN101111265A (pt)
AR (1) AR053541A1 (pt)
AU (1) AU2006210098A1 (pt)
BR (1) BRPI0607349A2 (pt)
CA (1) CA2595976A1 (pt)
GB (1) GB0502358D0 (pt)
GT (1) GT200600023A (pt)
IL (1) IL184713A0 (pt)
MA (1) MA29273B1 (pt)
MX (1) MX2007009436A (pt)
NO (1) NO20074497L (pt)
PE (1) PE20061203A1 (pt)
RU (1) RU2007132980A (pt)
TN (1) TNSN07304A1 (pt)
TW (1) TW200640487A (pt)
WO (1) WO2006082052A1 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006212866A1 (en) * 2005-02-08 2006-08-17 Novartis Ag Antilymphocyte antibody induction by combination of an S1P receptor agonist/modulator and of immunosuppressive drugs
TW201920257A (zh) 2008-04-11 2019-06-01 日商中外製藥股份有限公司 重複結合複數個抗原的抗原結合分子
PT3190128T (pt) * 2008-09-17 2019-02-07 Xencor Inc Composições e métodos para tratar distúrbios mediados pela ige
JP5843783B2 (ja) * 2009-12-18 2016-01-13 サノフイ ＧＰＶＩに対する新規アンタゴニスト抗体および該抗体のＦａｂフラグメントならびにこれらの使用
TWI654203B (zh) 2010-11-30 2019-03-21 Chugai Seiyaku Kabushiki Kaisha 具有鈣依存性的抗原結合能力之抗體
SG10201609665PA (en) 2011-02-25 2017-01-27 Chugai Pharmaceutical Co Ltd FcɣRIIb-SPECIFIC Fc ANTIBODY
AR085749A1 (es) * 2011-04-01 2013-10-23 Novartis Ag Formulaciones
JP6322411B2 (ja) 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
MX2017005774A (es) 2014-12-19 2017-07-28 Chugai Pharmaceutical Co Ltd Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso.
EA201791366A1 (ru) 2014-12-19 2018-02-28 Чугаи Сейяку Кабусики Кайся Антитела к c5 и способы их применения
CN114773469B (zh) 2015-02-05 2025-12-19 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用
TWI759261B (zh) 2015-02-27 2022-04-01 日商中外製藥股份有限公司 Ｉｌ－６受體抗體用於製備醫藥組成物的用途
US10947320B2 (en) 2015-12-18 2021-03-16 University Of Notre Dame Du Lac Covalent heterobivalent antibody inhibitors and ligands
EP3394098A4 (en) 2015-12-25 2019-11-13 Chugai Seiyaku Kabushiki Kaisha ANTI-MYOSTATIN ANTIBODIES AND METHOD OF USE
GB201610198D0 (en) 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies
CN116271014A (zh) 2016-08-05 2023-06-23 中外制药株式会社 用于预防或治疗il-8相关疾病的组合物
WO2018139623A1 (en) 2017-01-30 2018-08-02 Chugai Seiyaku Kabushiki Kaisha Anti-sclerostin antibodies and methods of use
JOP20190271A1 (ar) 2017-05-24 2019-11-21 Novartis Ag بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
DE102017215154A1 (de) 2017-08-30 2019-02-28 Markus Bläss Zusammensetzung zur topischen Behandlung von nicht-Mikroorganismus-verursachten entzündlichen Haut- und Schleimhauterkrankungen
WO2025010086A1 (en) 2023-07-05 2025-01-09 Genentech, Inc. Anti-ige antibody therapy for multiple food allergies

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6172213B1 (en) * 1997-07-02 2001-01-09 Genentech, Inc. Anti-IgE antibodies and method of improving polypeptides
US5994511A (en) * 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
GB0200429D0 (en) * 2002-01-09 2002-02-27 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
KR20070100344A (ko) 2007-10-10
EP1846031A1 (en) 2007-10-24
MX2007009436A (es) 2007-08-17
US20080206237A1 (en) 2008-08-28
TW200640487A (en) 2006-12-01
IL184713A0 (en) 2007-12-03
GT200600023A (es) 2006-08-16
TNSN07304A1 (en) 2008-12-31
AR053541A1 (es) 2007-05-09
CN101111265A (zh) 2008-01-23
GB0502358D0 (en) 2005-03-16
JP2008528650A (ja) 2008-07-31
WO2006082052A1 (en) 2006-08-10
RU2007132980A (ru) 2009-03-10
MA29273B1 (fr) 2008-02-01
PE20061203A1 (es) 2006-12-19
AU2006210098A1 (en) 2006-08-10
NO20074497L (no) 2007-10-26
CA2595976A1 (en) 2006-08-10

Similar Documents

Publication Publication Date Title
TNSN07304A1 (en) Combination of xolair with immunosuppressive agent
BRPI0718523B8 (pt) Forma de dosagem, e, método para preparar a forma de dosagem
AR106702A2 (es) Uso de un anticuerpo antagonista anti-ngf para la preparación de un medicamento
UA89798C2 (ru) Стабильный водный препарат антитела в гистидинацетатном буфере
JP2012509886A5 (pt)
TNSN08511A1 (en) Lyophilized formulations of anti-egfr antibodies
BRPI0513841A (pt) composto, composição farmacêutica, e uso do composto
WO2004089396A3 (en) Anti-fungal peptidomimetics
AR071852A1 (es) Formulacion farmaceutica de un anticuerpo frente a ox40l
CO6761350A2 (es) Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogenesis
AR080795A1 (es) Anticuerpos anti-lrp6 (proteina relacionada con el receptor ldl tipo 6)
CL2007001049A1 (es) Uso de un compuesto que altera al receptor de interleuquina 1 (il-1) para el tratamiento de enfermedades o trastornos oftalmicos; y composicion farmaceutica que comprende el compuesto il-1.
AR073717A1 (es) Anticuerpos anti-notch2 de murino y humano, y metodos de uso
EA200970469A1 (ru) Антитела-агонисты рецептора trkb и их применение
CL2004000930A1 (es) Compuesto derivado de dihidroquinazolina de formula definida, util para el tratamiento y/o profilaxis de infecciones virales; composicion farmaceutica que comprende al compuesto y uso del compuesto en la preparacion de medicamentos.
BRPI0516531A (pt) imunoterapia de distúrbios auto-imunes
ATE556717T1 (de) Neutralisierung monoklonaler antikörper gegen mit schwerem akutem respirationssyndrom assoziiertem coronavirus
BRPI0512878A (pt) formulações de suspensão de aerossol, com tg 227 ea ou tg 134 a como agente propulsor
ES2616017T3 (es) Composiciones que contienen sulfato de condroitina, nattocinasa y compuestos de sulfhidrilo para su uso en el tratamiento de inflamación
EP2000541A4 (en) HUMANIZED MONOCLONAL ANTI-CD20 ANTIBODY
CL2007002619A1 (es) Compuestos derivados de 3-aza-biciclo[4.1.0]heptano; composicion farmaceutica; y uso en el tratamiento de la depresion.
IL179240A (en) Use of an antibody bound to the complement component 5c for the preparation of drugs to assess the survival of an implant, and pharmaceutical packaging and injection kits containing this antibody
EP2311876A3 (en) M-CSF-specific monoclonal antibody and uses thereof
BR0306732A (pt) Tratamentos em combinação para doença alérgica compreendendo a administração de um anticorpo anti-ige e composto antialérgico
UY27727A1 (es) Nueva composicion farmacéutica-

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]